These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38782015)

  • 21. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
    Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
    Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
    Fehlings MG; Badhiwala JH; Ahn H; Farhadi HF; Shaffrey CI; Nassr A; Mummaneni P; Arnold PM; Jacobs WB; Riew KD; Kelly M; Brodke DS; Vaccaro AR; Hilibrand AS; Wilson J; Harrop JS; Yoon ST; Kim KD; Fourney DR; Santaguida C; Massicotte EM; Kopjar B
    Lancet Neurol; 2021 Feb; 20(2):98-106. PubMed ID: 33357512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial.
    ;
    Lancet Neurol; 2015 Sep; 14(9):883-892. PubMed ID: 26234554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial.
    Gonzalez-Bermejo J; Morélot-Panzini C; Tanguy ML; Meininger V; Pradat PF; Lenglet T; Bruneteau G; Forestier NL; Couratier P; Guy N; Desnuelle C; Prigent H; Perrin C; Attali V; Fargeot C; Nierat MC; Royer C; Ménégaux F; Salachas F; Similowski T
    Lancet Neurol; 2016 Nov; 15(12):1217-1227. PubMed ID: 27751553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
    Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
    Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
    BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.
    Lauria G; Dalla Bella E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Fazio R; Filosto M; Giannini F; Granieri E; La Bella V; Logroscino G; Mandrioli J; Mazzini L; Monsurrò MR; Mora G; Pietrini V; Quatrale R; Rizzi R; Salvi F; Siciliano G; Sorarù G; Volanti P; Tramacere I; Filippini G;
    J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):879-86. PubMed ID: 25595151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
    Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
    Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V;
    Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis.
    Phukan J
    IDrugs; 2010 Jul; 13(7):482-96. PubMed ID: 20582873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.
    Camu W; Mickunas M; Veyrune JL; Payan C; Garlanda C; Locati M; Juntas-Morales R; Pageot N; Malaspina A; Andreasson U; Kirby J; Suehs C; Saker S; Masseguin C; De Vos J; Zetterberg H; Shaw PJ; Al-Chalabi A; Leigh PN; Tree T; Bensimon G
    EBioMedicine; 2020 Sep; 59():102844. PubMed ID: 32651161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
    Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arimoclomol: a potential therapy under development for ALS.
    Lanka V; Wieland S; Barber J; Cudkowicz M
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1907-18. PubMed ID: 19938902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.
    Wills AM; Hubbard J; Macklin EA; Glass J; Tandan R; Simpson EP; Brooks B; Gelinas D; Mitsumoto H; Mozaffar T; Hanes GP; Ladha SS; Heiman-Patterson T; Katz J; Lou JS; Mahoney K; Grasso D; Lawson R; Yu H; Cudkowicz M;
    Lancet; 2014 Jun; 383(9934):2065-2072. PubMed ID: 24582471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.